Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 5/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869732 | 1.00 | CTSL (0.48) | CTSLCTSSCTSKCTSBMAPK1 | |
| SCHEMBL5869727 | 1.00 | CTSL (0.48) | CTSLCTSSCTSKCTSBMAPK1 | |
| SCHEMBL5869949 | 0.83 | MMP2 (0.53) | MMP3 | |
| SCHEMBL5869951 | 0.83 | MMP2 (0.53) | MMP3 | |
| SCHEMBL5869945 | 0.83 | MMP2 (0.53) | MMP3 | |
| SCHEMBL5869702 | 0.82 | ALDH1A1 (0.54) | CTSSMMP3SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5869715 | 0.82 | ALDH1A1 (0.54) | CTSSMMP3SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5869706 | 0.82 | ALDH1A1 (0.54) | CTSSMMP3SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5869667 | 0.81 | MMP9 (0.56) | MMP3 | |
| SCHEMBL5869671 | 0.81 | MMP9 (0.56) | MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | CTSL 911/4885CTSS 751/4885CTSK 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.